StockData
Bio-Rad Laboratories, Inc. logo

Bio-Rad Laboratories, Inc. (BIO) stock

BIONYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO.B
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value
$372.18−12.22 (-3.18%)

Close on Oct 30, 2026Market cap $9.99BP/E 45.3Yield –

Earnings

Bio-Rad Laboratories's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Oct 28, 2026
Q3 FY2026 · estimated, during market hours
Revenue, Q2 FY2026
$651.00M
-0.1% on a year earlier
Non-GAAP diluted income per share, Q2 FY2026
$2.62
$2.61 a year earlier
Latest guidance
Reaffirmed
Aug 4, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Bio-Rad Laboratories's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Oct 28, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 4, 2026during market hours$651.00M-0.1%$13.85$2.62Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026during market hours$592.10M+1.1%––Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026during market hours$693.20M+3.9%$26.65$2.51Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025during market hours$653.00M+0.5%-$12.70$2.26Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025during market hours$651.60M+2.1%$11.67$2.61Release
Q1 FY2025ended Mar 31, 2025May 1, 2025during market hours$585.40M-4.2%$2.29$2.54Release
Q4 FY2024ended Dec 31, 2024Feb 13, 2025during market hours$667.50M-2.0%-$25.57$2.90Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024during market hours$649.70M+2.8%$23.34$2.01Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024during market hours$638.50M-6.3%-$76.26$3.11Release
Q1 FY2024ended Mar 31, 2024May 7, 2024during market hours$610.80M-9.8%$13.45$2.29Release
Q4 FY2023ended Dec 31, 2023Feb 15, 2024during market hours$681.20M-6.7%$12.14$3.10Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Bio-Rad Laboratories's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
currency-neutral revenuenon-GAAPFY2026-3% – +0.5%-3% – +0.5%ReaffirmedAug 4, 2026
operating marginnon-GAAPFY202610% – 12%10% – 12%ReaffirmedAug 4, 2026

Guidance history

Every forecast Bio-Rad Laboratories put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 4, 2026operating marginFY202610% – 12%Reaffirmed
Aug 4, 2026currency-neutral revenueFY2026-3% – +0.5%Reaffirmed
Apr 30, 2026operating marginFY202610% – 12%Lowered
Apr 30, 2026currency-neutral revenueFY2026-3% – +0.5%Lowered
Feb 12, 2026estimated non-GAAP operating marginFY202612% – 12.5%New
Feb 12, 2026non-GAAP, currency neutral revenue growthFY2026+0.5% – +1.5%New
Oct 29, 2025non-GAAP operating marginFY202512% – 13%New
Oct 29, 2025non-GAAP, currency-neutral revenue growthFY20250% – +1%New
Jul 31, 2025Non-GAAP operating marginFY202512% – 13%Raised
Jul 31, 2025non-GAAP, currency-neutral revenue growthFY20250% – +1%Narrowed
May 1, 2025operating marginFY202510% – 12%Lowered
May 1, 2025currency-neutral revenueFY2025-1% – +1.5%Lowered
Feb 13, 2025estimated non-GAAP operating marginFY202513% – 13.5%New
Feb 13, 2025non-GAAP, currency-neutral revenue growthFY2025+1.5% – +3.5%Lowered
Oct 30, 2024operating marginFY202412.75% – 13.25%Raised
Oct 30, 2024revenueFY2024-4% – -2.5%Reaffirmed
Aug 1, 2024non-GAAP operating marginFY202412% – 13%Lowered
Aug 1, 2024non-GAAP revenueFY2024-4% – -2.5%Lowered
May 7, 2024estimated non-GAAP operating marginFY202413.5% – 14%Reaffirmed
May 7, 2024non-GAAP, currency-neutral revenue growthFY2024+1% – +2.5%Reaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Bio-Rad Laboratories filed with the SEC as exhibits to Form 8-K or 6-K

  1. Bio-Rad Reports Second -Quarter 2026 Financial Results
    Results
  2. Supplemental Earnings Results Presentation August 4, 2026 Second Quarter 2026 Financial Results
    Results
  3. Bio-Rad Reports First -Quarter 2026 Financial Results
    Results
  4. Supplemental Earnings Results Presentation April 30, 2026 First Quarter 2026 Financial Results
    Results
  5. Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
    Results
  6. Supplemental Earnings Results Presentation February 12, 2026 Fourth-Quarter and Full-Year 2025 Results
    Results
  7. Bio-Rad Reports Third -Quarter 2025 Financial Results
    Results
  8. October 29, 2025 Third Quarter 2025 Financial Results Bio-Rad Laboratories, Inc.
    Results
  9. Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away
    Update
  10. Bio-Rad Laboratories, Inc. NYSE: BIO and BIO.B August 26, 2025 Droplet Digital PCR – Powering the Future
    Update
  11. Bio-Rad Reports Second -Quarter 2025 Financial Results
    Results
  12. Quarterly results release
    Results
  13. Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
    News
  14. Bio-Rad Reports First -Quarter 2025 Financial Results
    Results
  15. Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
    Results